Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia flag Australia · Delayed Price · Currency is AUD
4.330
+0.120 (2.85%)
Jul 29, 2025, 4:10 PM AEST
2.85%
Market Cap1.57B
Revenue (ttm)10.78M
Net Income (ttm)-48.70M
Shares Out371.89M
EPS (ttm)-0.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,275,717
Average Volume3,349,401
Open4.300
Previous Close4.210
Day's Range4.240 - 4.700
52-Week Range1.430 - 8.980
Beta1.63
RSI75.22
Earnings DateAug 22, 2025

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 50
Stock Exchange Australian Securities Exchange
Ticker Symbol CU6
Full Company Profile

Financial Performance

In 2024, Clarity Pharmaceuticals's revenue was 11.51 million, an increase of 17.41% compared to the previous year's 9.80 million. Losses were -42.32 million, 72.0% more than in 2023.

Financial Statements

News

Clarity Pharmaceuticals readies mega capital raising

Stockbroker Bell Potter in Melbourne is the sole lead manager on the deal, which is slated to launch on Monday.

1 day ago - The Australian Financial Review

Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK

Indoco Remedies witnessed a significant 8% jump in its stock price following the announcement of a strategic distribution partnership with Clarity Pharma, UK. This collaboration is set to launch appro...

8 months ago - Business Upturn

Indoco Remedies partners with Clarity Pharma to strengthen UK presence

The partnership combines Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s extensive distribution network and market expertise.

8 months ago - Business Upturn

Rising Shares at Clarity Pharmaceuticals as it Launches Second Phase III Trial and Promotes Michelle Parker to CEO

Biotech firm Clarity Pharmaceuticals is preparing to initiate a second Phase III clinical trial for its prostate cancer diagnostic product, 64Cu-SAR-bisPSMA, after receiving positive feedback from the...

10 months ago - CEOWORLD magazine

Three ASX companies jockeying to be the next biotech winners

Clarity Pharmaceuticals reports it eliminated prostate cancer in a patient; LTR Pharma wants to sell nasal viagra; and Opthea has clinical trial results soon.

1 year ago - The Australian Financial Review